Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNNMedical - Instruments & Supplies
+$0.37 today
- Market cap
- $158.01M
- Beta
- 4.34
- P/E (TTM)
- 99.1
- EPS (TTM)
- $0.16
Volume 0.09M
Average 0.03M
NNNN Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN
Short-term Investments · Q4 FY2025 · quarter ended Dec 2025
Short-term investments remains negative
Q4 FY2025 short-term investments was $4.13M, compared with $0 a year earlier. Over 3 fiscal years it compounded at +38.2% a year.
Context
- Short-term investments amounted to 13.7% of total assets at the end of Q4 FY2025, up 13.7 pp from a year earlier.
- Short-term investments increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 4.13M USD
- Year-over-year change
- —
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.13M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 1.57M | — |
| FY2021 | 2021-12-31 | 0 | — |
Short-term Investments vs competitors
How NNNN compares with its peers on the latest reported figures
- Peers report in different currencies, so short-term investments is compared through growth and share of total assets rather than absolute size.
- Short-term investments amounts to 13.7% of total assets for NNNN, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $122.27M USD | +289.8% | +50.2% | 24.2% | |
| Dec 2025 | $70.87M USD | — | — | 21.1% | |
| Mar 2026 | $58.19M USD | -74.6% | -11.6% | 45.1% | |
| Mar 2026 | $52.8M USD | +9.4% | — | 38.8% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | Dec 2025 | $4.13M USD | — | +38.2% | 13.7% |
| Mar 2026 | CA$500.65K CAD | -85.6% | -74.0% | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Feb 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding NNNN) | — | -32.6% | -11.6% | 0.0% | |
Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
Intrinsic Alpha fair value
Locked
Current Price
$3.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.